Free Trial

Cellebrite DI (CLBT) 10K Form and Latest SEC Filings 2026

Cellebrite DI logo
$12.89 -0.29 (-2.20%)
As of 04:00 PM Eastern

Latest Cellebrite DI SEC Filings & Recent Activity

Cellebrite DI (NASDAQ:CLBT) has submitted 215+ documents to the U.S. Securities and Exchange Commission (SEC) since 2021. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Cellebrite DI's financial statements. The most recent filing was a Form 4 submitted on May 26, 2026.

Form 4
Cellebrite DI Ltd. Reports Ownership Change on May. 26, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

20-F
Cellebrite DI Files Annual Report on Mar. 3, 2026

The 20-F contains Cellebrite DI's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Cellebrite DI SEC Filing History

Browse Cellebrite DI's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/26/2026 3:06 PM
Cellebrite DI (1854587) Issuer
GEE DAVID NICHOLAS (1547134) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 3:49 PM
Cellebrite DI (1854587) Subject
GEE DAVID NICHOLAS (1547134) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/19/2026 7:39 AM
Cellebrite DI (1854587) Issuer
Jewell Marcus (1875661) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:06 PM
Cellebrite DI (1854587) Issuer
Ramji Shiven (2133891) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 6:15 AM
Cellebrite DI (1854587) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/12/2026 5:15 PM
Cellebrite DI (1854587) Subject
Jewell Marcus (1875661) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/12/2026 4:39 PM
Cellebrite DI (1854587) Subject
GEE DAVID NICHOLAS (1547134) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/07/2026 9:31 AM
Cellebrite DI (1854587) Issuer
Ramji Shiven (2133891) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 2:04 PM
Cellebrite DI (1854587) Issuer
Utsumi Ryusuke (1971298) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 2:17 PM
Cellebrite DI (1854587) Issuer
Domnitz Yonatan (1970748) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:23 AM
Armon Ronnen (1970877) Reporting
Cellebrite DI (1854587) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:11 AM
Cellebrite DI (1854587) Issuer
Gruber Dafna (1971695) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:25 AM
Cellebrite DI (1854587) Issuer
Shavit Sigalit (2041387) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:26 AM
Cellebrite DI (1854587) Issuer
Hogan Thomas E. (2013619) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:27 AM
Cellebrite DI (1854587) Issuer
Richardson Troy (1833357) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:28 AM
Cellebrite DI (1854587) Issuer
Tadmor-Eilat Zohar (1970909) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:13 AM
Barter David (1706672) Reporting
Cellebrite DI (1854587) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:14 AM
Cellebrite DI (1854587) Issuer
GEE DAVID NICHOLAS (1547134) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:16 AM
Cellebrite DI (1854587) Issuer
Windham Holly B. (1815199) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:17 AM
Cellebrite DI (1854587) Issuer
Jewell Marcus (1875661) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:15 AM
Cellebrite DI (1854587) Issuer
CLAMMER ADAM (1192808) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/03/2026 3:07 PM
Cellebrite DI (1854587) Filer
Form 20-F
Registration statement / Annual report / Transition report  
02/24/2026 5:00 AM
Cellebrite DI (1854587) Subject
SUNCORPORATION (1651022) Filed by
Form SCHEDULE 13G/A
02/18/2026 3:37 PM
Cellebrite DI (1854587) Subject
Jewell Marcus (1875661) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/17/2026 5:46 PM
Cellebrite DI (1854587) Subject
Jewell Marcus (1875661) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/12/2026 4:16 PM
Cellebrite DI (1854587) Subject
GEE DAVID NICHOLAS (1547134) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/11/2026 6:15 AM
Cellebrite DI (1854587) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/02/2025 7:15 AM
Cellebrite DI (1854587) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/24/2025 3:31 PM
Cellebrite DI (1854587) Subject
GEE DAVID NICHOLAS (1547134) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/21/2025 3:13 PM
Cellebrite DI (1854587) Subject
GEE DAVID NICHOLAS (1547134) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/20/2025 5:48 PM
Cellebrite DI (1854587) Subject
Gruber Dafna (1971695) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2025 3:10 PM
Cellebrite DI (1854587) Subject
Shapira Ayala Berler (2027071) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2025 3:22 PM
Cellebrite DI (1854587) Subject
Jewell Marcus (1875661) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/17/2025 7:26 PM
Cellebrite DI (1854587) Subject
Jewell Marcus (1875661) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/06/2025 3:05 PM
Cellebrite DI (1854587) Subject
Gerner Dana (1970804) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/24/2025 3:48 PM
Cellebrite DI (1854587) Subject
Keinan Elly (1883311) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/23/2025 3:21 PM
Armon Ronnen (1970877) Reporting
Cellebrite DI (1854587) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/22/2025 8:37 PM
Cellebrite DI (1854587) Subject
Hogan Thomas E. (2013619) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/22/2025 7:21 AM
Cellebrite DI (1854587) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/19/2025 3:03 PM
Cellebrite DI (1854587) Subject
Gerner Dana (1970804) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/11/2025 3:26 PM
Cellebrite DI (1854587) Subject
Gerner Dana (1970804) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Read this warning immediately (Ad)

Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel

Read Porter Stansberry's full breakdown and protect your wealth now
08/27/2025 3:26 PM
Cellebrite DI (1854587) Subject
Tadmor-Eilat Zohar (1970909) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/26/2025 5:28 PM
Cellebrite DI (1854587) Subject
Tadmor-Eilat Zohar (1970909) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/25/2025 7:01 PM
Cellebrite DI (1854587) Subject
Tadmor-Eilat Zohar (1970909) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/22/2025 3:44 PM
Cellebrite DI (1854587) Subject
GEE DAVID NICHOLAS (1547134) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/21/2025 5:30 PM
Cellebrite DI (1854587) Subject
GEE DAVID NICHOLAS (1547134) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/20/2025 3:26 PM
Cellebrite DI (1854587) Subject
Shapira Ayala Berler (2027071) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/20/2025 3:02 PM
Cellebrite DI (1854587) Subject
Gruber Dafna (1971695) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/19/2025 3:29 PM
Cellebrite DI (1854587) Subject
Jewell Marcus (1875661) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/18/2025 4:09 PM
Cellebrite DI (1854587) Subject
Jewell Marcus (1875661) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/15/2025 8:01 AM
Cellebrite DI (1854587) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/14/2025 6:10 AM
Cellebrite DI (1854587) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/08/2025 7:45 AM
Cellebrite DI (1854587) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/05/2025 6:45 AM
Cellebrite DI (1854587) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

Cellebrite DI SEC Filings - Frequently Asked Questions

Cellebrite DI (CLBT) has submitted 215+ filings to the SEC since 2021. You can browse the complete history or filter by form type using the tools above.

Cellebrite DI's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Cellebrite DI's financial statements page.

The most recent filing was a Form 4 submitted on May 26, 2026. This was an insider ownership change filed by 4 - Cellebrite DI Ltd. (0001854587) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:CLBT) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners